CriticalSoluble guanylate cyclase (sGC) stimulator×Phosphodiesterase type 5 (PDE-5) inhibitor
Updated · Methodology
Mechanism
Both raise cGMP. Synergistic systemic hypotension. FDA Adempas Section 4.3 strict contraindication.
Symptoms
Severe hypotension, syncope.
Management
Combination contraindicated.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- EMA: Adempas (riociguat) SmPC, Section 4.3 (2024)– EMA EPAR Adempas
- AEMPS: Ficha técnica: Tadalafilo (nº registro 85659), sección 4.3 (2025)– AEMPS, CIMA, nº registro 85659, revisión 12/2025, sección 4.3